We are live on !
Find out more
Armistice Capital Portfolio holdings
AUM
$8.17B
Turnover
62.5%
1-Year Est. Return
68.82%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$8.17B
AUM Growth
+$2.55B
(+45%)
Cap. Flow
+$12.3M
Cap. Flow % of AUM
Cap. Flow %
0.15%
Top 10 Holdings %
Top 10 Hldgs %
61.52%
Holding
432
New
171
Increased
73
Reduced
69
Closed
99
Avg Time Held
Equity + Options
0.9
years
Top 10 Avg Time Held
Equity + Options
1.8
years
Top 20 Avg Time Held
Equity + Options
1.8
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
1.8
years
Top 20 Avg Time Held Equity only
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$36.5M |
| 2 |
Supernus Pharmaceuticals
SUPN
|
+$36.1M |
| 3 |
Sanofi
SNY
|
+$34.1M |
| 4 |
Cytokinetics
CYTK
|
+$31.4M |
| 5 |
Waters Corp
WAT
|
+$25.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$147M |
| 2 |
PTC Therapeutics
PTCT
|
+$72.4M |
| 3 |
Immunovant
IMVT
|
+$55.7M |
| 4 |
Datadog
DDOG
|
+$31.8M |
| 5 |
Avanos Medical
AVNS
|
+$28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 55.89% |
| 2 | Healthcare | 30.09% |
| 3 | Technology | 6.58% |
| 4 | Consumer Discretionary | 3.42% |
| 5 | Communication Services | 1.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$818B
| $2.39B | 29.24% |
3,200,000
+1,100,000
| +52% | +$798M |
2022 Q3
15 quarters
|
|
2
PUT
iShares Russell 2000 ETF
IWM
$77.8B
| $1.74B | 21.32% |
5,800,000
+2,300,000
| +66% | +$646M |
2022 Q3
15 quarters
|
|
3
Madrigal Pharmaceuticals
MDGL
$10.3B
| $155M | 1.89% |
288,000
+23,417
| +9% | +$12M |
2019 Q1
29 quarters
|
|
|
4
CALL
Cytokinetics
CYTK
$8.7B
| $130M | 1.59% |
1,530,000
-170,000
| -10% | -$12.2M |
2024 Q1
9 quarters
|
|
|
5
Supernus Pharmaceuticals
SUPN
$2.32B
| $123M | 1.51% |
2,646,201
+750,854
| +40% | +$36.1M |
2019 Q4
26 quarters
|
|
6
CALL
Agios Pharmaceuticals
AGIO
$2.07B
| $104M | 1.28% |
2,810,000
-390,000
| -12% | -$11.8M |
2025 Q3
3 quarters
|
|
|
7
Cytokinetics
CYTK
$8.7B
| $102M | 1.25% |
1,201,342
+436,804
| +57% | +$31.4M |
2024 Q1
9 quarters
|
|
8
Incyte
INCY
$23B
| $102M | 1.25% |
900,005
+243,188
| +37% | +$24.1M |
2019 Q2
28 quarters
|
|
9
Neurocrine Biosciences
NBIX
$13.9B
| $90.3M | 1.1% |
535,838
-188,162
| -26% | -$27.9M |
2022 Q1
17 quarters
|
|
|
10
Travere Therapeutics
TVTX
$4.76B
| $89.3M | 1.09% |
1,572,539
-3,324,878
| -68% | -$147M |
2021 Q1
21 quarters
|
|
|
11
Agios Pharmaceuticals
AGIO
$2.07B
| $89.1M | 1.09% |
2,400,000
-316,000
| -12% | -$9.6M |
2022 Q3
15 quarters
|
|
|
12
PTC Therapeutics
PTCT
$5.15B
| $87.4M | 1.07% |
1,071,395
-1,003,054
| -48% | -$72.4M |
2019 Q3
27 quarters
|
|
13
UnitedHealth
UNH
$365B
| $76.1M | 0.93% |
183,000
+35,000
| +24% | +$13M |
2026 Q1
1 quarter
|
|
14
Freshpet
FRPT
$3.17B
| $74.5M | 0.91% |
1,260,702
+167,395
| +15% | +$9.6M |
2025 Q1
5 quarters
|
|
15
Dyne Therapeutics
DYN
$2.86B
| $68.6M | 0.84% |
3,087,226
-87,884
| -3% | -$1.63M |
2023 Q2
12 quarters
|
|
16
Amazon
AMZN
$2.83T
| $67.8M | 0.83% |
284,562
+22,425
| +9% | +$5.63M |
2022 Q2
16 quarters
|
|
|
17
Immunovant
IMVT
$5.71B
| $66.9M | 0.82% |
1,736,000
-1,828,916
| -51% | -$55.7M |
2023 Q3
11 quarters
|
|
18
Rigel Pharmaceuticals
RIGL
$873M
| $65.4M | 0.8% |
1,672,000
+392,000
| +31% | +$12.1M |
2022 Q3
15 quarters
|
|
19
Thermo Fisher Scientific
TMO
$251B
| $61.4M | 0.75% |
122,480
+30,989
| +34% | +$14.9M |
2025 Q2
4 quarters
|
|
20
Ironwood Pharmaceuticals
IRWD
$587M
| $58.7M | 0.72% |
13,932,000
-1,096,000
| -7% | -$4.22M |
2023 Q3
11 quarters
|
|
21
Harmony Biosciences
HRMY
$2.18B
| $56.9M | 0.7% |
1,564,000
-60,000
| -4% | -$1.89M |
2025 Q4
2 quarters
|
|
|
22
Regeneron Pharmaceuticals
REGN
$80.6B
| $56M | 0.69% |
89,809
+53,683
| +149% | +$36.5M |
2019 Q2
28 quarters
|
|
|
23
CALL
PTC Therapeutics
PTCT
$5.15B
| $53.8M | 0.66% |
660,000
+270,000
| +69% | +$19.5M |
2026 Q1
1 quarter
|
|
24
Nektar Therapeutics
NKTR
$1.25B
| $50.5M | 0.62% |
724,000
+146,000
| +25% | +$10.7M |
2024 Q2
8 quarters
|
|
25
Mineralys Therapeutics
MLYS
$1.85B
| $46.8M | 0.57% |
1,736,000
+560,000
| +48% | +$15.4M |
2025 Q2
4 quarters
|
|
Similar funds
Armistice Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Armistice Capital held 432 positions worth $8.17B, up 45% from $5.62B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Armistice Capital's Q2 2026 filing shows 171 new, 73 increased, 69 reduced and 99 closed positions. Its largest new stake was Waters Corp: 75,004 shares worth $28.1M. The largest sale was Travere Therapeutics, an estimated $147M.
By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.
- Armistice Capital's largest Q2 2026 buy was Waters Corp: 75,004 shares worth $28.1M.
- Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2026, an estimated $36.5M increase.
- Armistice Capital's biggest Q2 2026 reduction was Travere Therapeutics, cutting an estimated $147M.
- Armistice Capital fully exited Avanos Medical in Q2 2026, selling an estimated $28M.
- Armistice Capital's ten largest holdings make up 62% of its $8.17B portfolio in Q2 2026.
- Armistice Capital opened 171 new positions and closed 99 in Q2 2026.
- Armistice Capital's portfolio value rose 45% quarter-over-quarter to $8.17B.
Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.